Small-cap CNS outfit inks API deal for preclinical MEK inhibitor
Miami-based penny stock player Pasithea Therapeutics is teaming with CDMO WuXi STA to make the active pharmaceutical ingredient for its lead preclinical drug — completing one of its last major requirements to submit an IND to the FDA.
CEO Tiago Reis Marques tells Endpoints News that the deal, announced Wednesday, is for one kilogram of the active ingredient for PAS-004, Pasithea’s lead drug, and that Pasithea hopes it will be enough API for both Phase I and Phase II trials.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.